<SEC-DOCUMENT>0001104659-24-125957.txt : 20241205
<SEC-HEADER>0001104659-24-125957.hdr.sgml : 20241205
<ACCEPTANCE-DATETIME>20241205172123
ACCESSION NUMBER:		0001104659-24-125957
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20241205
FILED AS OF DATE:		20241205
DATE AS OF CHANGE:		20241205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Profound Medical Corp.
		CENTRAL INDEX KEY:			0001628808
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39032
		FILM NUMBER:		241529923

	BUSINESS ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5
		BUSINESS PHONE:		647-476-1350

	MAIL ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Profound Medical Inc.
		DATE OF NAME CHANGE:	20141222
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2430237d2_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of December&nbsp;2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number:&nbsp;<B>001-39032</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 14pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PROFOUND MEDICAL
CORP.</B></FONT><BR>
(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2400 Skymark Avenue, Unit 6, Mississauga, Ontario
L4W 5K5</B><BR>
(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.<BR>
Form&nbsp;20-F <FONT STYLE="font-family: Wingdings">&#168;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibits&nbsp;99.1 and 99.2 to this report on Form&nbsp;6-K
are hereby incorporated by reference as Exhibits&nbsp;to the&nbsp;Registration Statement on Form&nbsp;F-10 of Profound Medical Corp.
(<U><A HREF="https://www.sec.gov/Archives/edgar/data/1628808/000110465924071819/tm2417174-1_f10.htm" STYLE="-sec-extract: exhibit">File No.&nbsp;333-280236</A></U>), as amended and supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following document is attached as an exhibit hereto and is incorporated
by reference herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 15%"><B>Exhibit</B></TD>
    <TD STYLE="width: 85%"><B>Title</B></TD></TR>
  <TR>
    <TD><A HREF="tm2430237d2_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD><A HREF="tm2430237d2_ex99-1.htm" STYLE="-sec-extract: exhibit">Consent of Mintz LLP</A></TD></TR>
  <TR>
    <TD><A HREF="tm2430237d2_ex99-2.htm" STYLE="-sec-extract: exhibit">99.2</A></TD>
    <TD><A HREF="tm2430237d2_ex99-2.htm" STYLE="-sec-extract: exhibit">Consent of Osler, Hoskin&nbsp;&amp; Harcourt LLP</A></TD></TR>
  <TR>
    <TD><A HREF="tm2430237d2_ex99-3.htm" STYLE="-sec-extract: exhibit">99.3</A></TD>
    <TD><A HREF="tm2430237d2_ex99-3.htm" STYLE="-sec-extract: exhibit">Press Release dated December&nbsp;5, 2024</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><B>PROFOUND MEDICAL CORP.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Registrant)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: December&nbsp;5, 2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">/s/ Rashed Dewan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Rashed Dewan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2430237d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 40%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 17%; font-size: 10pt"><IMG SRC="tm2430237d2_ex99-1img001.jpg" ALT=""></TD>
    <TD STYLE="width: 43%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">200 Bay Street, South Tower</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Suite&nbsp;2800</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Toronto, ON</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">647 499 2828</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">mintz.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2400 Skymark Avenue, Unit 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mississauga, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">L4W 5K5, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration
Statement on Form&nbsp;F-10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the references to our firm
name in the prospectus filed as part of this registration statement on Form&nbsp;F-10 of Profound Medical Corp. In giving this consent,
we do not thereby admit that we come within the category of persons whose consent is required by the Securities Act of 1933, as amended,
or the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ &ldquo;Mintz LLP&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mintz LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON MINTZ LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm2430237d2_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 51%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Osler, Hoskin&nbsp;&amp; Harcourt <FONT STYLE="font-variant: small-caps">llp</FONT></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Box 50, 1 First Canadian Place<BR>
    Toronto, Ontario, Canada&nbsp;&nbsp;M5X&nbsp;1B8<BR>
    416.362.2111&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">main</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">416.862.6666&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">facsimile</FONT></P></TD>
    <TD STYLE="width: 14%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 35%; font-size: 10pt"><IMG SRC="tm2430237d2_ex99-2img001.jpg" ALT=""></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toronto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Montr&eacute;al</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ottawa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calgary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New&nbsp;York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2400 Skymark Avenue, Unit #6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mississauga, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs/Mesdames:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Profound Medical Corp. (the &ldquo;Issuer&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We refer you to the prospectus supplement dated
December&nbsp;5, 2024 to the short form base shelf prospectus of the Issuer dated July&nbsp;10, 2024 filed in all provinces and territories
of Canada (the &ldquo;<B>Prospectus Supplement</B>&rdquo;), forming part of the Registration Statement on Form&nbsp;F-10, as amended
(Registration No.&nbsp;333-280236) filed by the Issuer with the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the references to this firm
on the second cover page&nbsp;and under the headings &ldquo;Documents Filed as Part&nbsp;of the Registration Statement&rdquo; and &ldquo;Interest
of Experts&rdquo; and to the reference to and use of our opinion under the heading &ldquo;Eligibility For Investment&rdquo; in the Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In giving this consent, we do not thereby admit
that we come within the category of persons whose consent is required by the <I>Securities Act</I> of 1933, as amended, or the rules&nbsp;and
regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours very truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&ldquo;Osler, Hoskin&nbsp;&amp; Harcourt LLP&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Osler, Hoskin&nbsp;&amp; Harcourt LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>tm2430237d2_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.3&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Profound Medical Announces Proposed Public Offering
of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS
SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TORONTO, ON (December&nbsp;5, 2024) -- Profound
Medical Corp. (TSX: PRN; NASDAQ: PROF) (&ldquo;Profound&rdquo; or the &ldquo;Company&rdquo;) today announced that it intends to offer
and sell common shares (the &ldquo;Common Shares&rdquo;) in an underwritten public offering (the &ldquo;Offering&rdquo;). In addition,
Profound expects to grant the underwriters of the Offering a 30-day option to purchase up to an additional 15% of the Common Shares sold
in the Offering. All of the securities in the Offering are being offered by Profound. The Offering is subject to market conditions, and
there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds of the Offering are expected
to be used: (i)&nbsp;to fund the continued commercialization of the TULSA-PRO&reg; system in the United States, (ii)&nbsp;to fund the
continued development and commercialization of the TULSA-PRO&reg; system and the Sonalleve&reg; system globally, and (iii)&nbsp;for working
capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering is expected to be completed pursuant
to an underwriting agreement to be entered into between the Company and Raymond James Ltd. and Lake Street Capital Markets as co-lead
underwriters and joint bookrunners, and a third underwriter. The Offering is expected to take place in each of the provinces and territories
of Canada, except the province of Qu&eacute;bec, and in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering is expected to close on or about
December&nbsp;10, 2024, subject to customary closing conditions including, but not limited to, the receipt of all necessary approvals
including the approval of the Toronto Stock Exchange. Profound will notify the Nasdaq Capital Market in accordance with the rules&nbsp;of that exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Offering, the Company
has filed a preliminary prospectus supplement (the &ldquo;Preliminary Prospectus Supplement&rdquo;) and intends to file a subsequent
prospectus supplement (the &ldquo;Prospectus Supplement&rdquo;) to its short form base shelf prospectus dated July&nbsp;10, 2024
(the &ldquo;Base Shelf Prospectus&rdquo;) in each of the provinces and territories of Canada relating to the proposed Offering. The
Prospectus Supplement will also be filed in the United States with the U.S. Securities and Exchange Commission (the
 &ldquo;SEC&rdquo;) as part of the Company&rsquo;s effective registration statement on Form&nbsp;F-10 (File no. 333-280236), as
amended, previously filed under the multijurisdictional disclosure system adopted by the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Access to the Base Shelf Prospectus, the Prospectus
Supplement, and any amendments to the documents will be provided in accordance with securities legislation relating to procedures for
providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Base Shelf Prospectus is, and the Prospectus
Supplement will be (within two business days of the date hereof), accessible on SEDAR+ at www.sedarplus.com and on EDGAR at www.sec.gov.
The Common Shares are offered under the Prospectus Supplement. An electronic or paper copy of the Base Shelf Prospectus, the Prospectus
Supplement (when filed), and any amendment to the documents may be obtained without charge, from Raymond James Ltd., Scotia Plaza, 40
King St. W., 54th Floor, Toronto, Ontario M5H 3Y2, Canada, or by telephone at 416-777-7000 or by email at ECM-Syndication@raymondjames.ca
by providing the contact with an email address or address, as applicable. Copies of the Prospectus Supplement and the Base Shelf Prospectus
will be available on EDGAR at www.sec.gov or may be obtained without charge from Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800)
248-8863, or by email at prospectus@raymondjames.com, and from Lake Street Capital Markets, LLC, 920 2nd Ave S - Ste 700, Minneapolis,
MN 55402, prospectus@lakestreetcm.com, (612) 326-1305. The Base Shelf Prospectus
and Prospectus Supplement contain important, detailed information about the Company and the proposed Offering. Prospective investors
should read the Base Shelf Prospectus and Prospectus Supplement (when filed) before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No securities regulatory authority has either
approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any province, territory, state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, territory,
state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Profound Medical Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is a commercial-stage medical device
company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is commercializing TULSA-PRO&reg;, a
technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. Profound
is also commercializing Sonalleve&reg;, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and
palliative pain treatment of bone metastases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release includes forward-looking
statements regarding Profound and its business which may include, but is not limited to, the Offering, including the
Offering&rsquo;s timing, pricing, underwriters, size, terms, selling jurisdictions, closing, over-allotment option, and use of
proceeds; the availability and timing of the final prospectus supplement; and, the expectations regarding the efficacy and
commercialization of Profound&rsquo;s technology. Often, but not always, forward-looking statements can be identified by the use of
words such as &quot;plans&quot;, &quot;is expected&quot;, &quot;expects&quot;, &quot;scheduled&quot;, &quot;intends&quot;,
 &quot;contemplates&quot;, &quot;anticipates&quot;, &quot;believes&quot;, &quot;proposes&quot; or variations (including negative
variations) of such words and phrases, or state that certain actions, events or results &quot;may&quot;, &quot;could&quot;,
 &quot;would&quot;, &quot;might&quot; or &quot;will&quot; be taken, occur or be achieved. Such statements are based on the current
expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by
certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties
affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors,
the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important
factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements,
there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No
forward-looking statement can be guaranteed. Additional information about the risks and uncertainties of forward-looking statements
and the assumptions upon which they are based is contained in the Company&rsquo;s filings with securities regulators, which are
available electronically through SEDAR+ at www.sedarplus.com and EDGAR at www.sec.gov. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephen Kilmer&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">skilmer@profoundmedical.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T: 647.872.4849</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2430237d2_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2430237d2_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "! &0# 2(  A$! Q$!_\0
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M#ZOGK]J8!?VG?VC@H '_  OKXP\  #GXA^(R>!ZGGZUX3D^I_.OW/+\ERF.
MP<IX*E6JUZ,:O-5C"<8PLDXJ\7)RNU9WM9.^K/\ "7BSQ?\ %/#<6\7PPGB=
MQ[AL*N)\ZPN#PN&SF&$AAJ&5YIF&72AST:=1RC.=!3IP44E3Y54;JQU^^6_X
M*B_MT@D#X\S?^&]^$/I_V3VJO_#SO]N>662:+XXW%Q,C6Z%D^'OPJN8H9KA9
MXX!?6EKX$@N%@;RD99(6R"03DY%?!](X$FW> ^U!&N\!MJ+(\JHN<X199))
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MQ\K Z!?+V[0. N  !Q49;!(_>/TP(HRVSW<@<@]?H<4_L!V "@=@J@!0/0
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M\-8:GQVX\#N1^1Y'H>:K? 7X+?%GPI_P5<_;\^->N>"-=TOX7?$;X:_ JP\
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M,CNH='T[6Y]-T2SU#7;V*[N=-\+:UXW_ .$A_0[_ (*+>!?&GQ3_ &)/VC_
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F75:$/^JB_P"N:?\ H(HHJ8;OT_5 9]]_K5_ZYC_T)Z***U __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2430237d2_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2430237d2_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L )$# 2(  A$! Q$!_\0
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M'XG^,]4EN[]-#GLTU:YT;1I]%T7Q3J6CZ39R>'-':PT(PQ:5HNEVYSI[/<I
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M:/$&KV>BP:IJ]W'I=MJ.N:M?6UFL,,^HW4B&9_*O^(+7_@EWY9B/[07_  4
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1P^^7_P B?FOL:7G^/^9__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
